ARS Pharmaceuticals, Inc. (SPRY) Financial Statements
ARS Pharmaceuticals, Inc. (SPRY) reported trailing twelve-month revenue of $116.9M (up 4.1% year on year) and net income of -$215.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$196.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SPRYARS Pharmaceuticals, Inc.Follow SPRY — free
—
Price chart with a free account
- Market cap
- 400.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 1.3 | 0.0 | 89.1 | 84.3 | 116.9 | |
| Gross profit | — | 0.0 | — | — | — | |
| Research & development | 18.4 | 20.3 | 19.6 | 13.2 | 15.2 | |
| Operating income | -35.5 | -67.5 | -3.1 | -179.4 | -216.3 | |
| Pre-tax income | -34.7 | -54.4 | 8.3 | -171.4 | — | |
| Income tax | 0.0 | 0.0 | 0.3 | -0.1 | — | |
| Net income | -34.7 | -54.4 | 8.0 | -171.3 | -215.4 | |
| Diluted EPS ($) | -0.87 | -0.57 | 0.08 | -1.74 | -2.18 | |
| Diluted shares (mn) | 40.0 | 95.2 | 102.4 | 98.6 | — |
USD millions · SEC XBRL
ARS Pharmaceuticals, Inc. — questions
- What is ARS Pharmaceuticals, Inc.'s revenue?
- $116.9M over the twelve months to 2026-06-30, up 4.1% year on year, from its 10-Q and 10-K filings.
- What is ARS Pharmaceuticals, Inc.'s net income?
- -$215.4M over the twelve months to 2026-06-30.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- -$196.6M over the twelve months to 2026-06-30.
- What are ARS Pharmaceuticals, Inc.'s diluted earnings per share?
- $-2.18 over the twelve months to 2026-06-30.
Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.